Candidate drug therapies for molecularly defined subgroups of esophageal cancer identified from high-throughput drug screening. A phase II study of MK-2206, an allosteric inhibitor of AKT as ...
Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors No significant financial relationships to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback